{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:27:13Z","timestamp":1791822433925,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T00:00:00Z","timestamp":1766275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Univerzita Karlova v Praze","award":["Cooperatio No. 43\u2014Surgical Disciplines"],"award-info":[{"award-number":["Cooperatio No. 43\u2014Surgical Disciplines"]}]},{"DOI":"10.13039\/501100006490","name":"Fakultn\u00ed Nemocnice Plzen","doi-asserted-by":"crossref","award":["00669806"],"award-info":[{"award-number":["00669806"]}],"id":[{"id":"10.13039\/501100006490","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Horizon 2020","award":["N856620"],"award-info":[{"award-number":["N856620"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-32593-8","type":"journal-article","created":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T16:24:18Z","timestamp":1766334258000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Baseline and early changes in eosinophil count and neutrophil-to-eosinophil ratio predict outcomes in metastatic renal cell carcinoma treated with nivolumab"],"prefix":"10.1038","volume":"16","author":[{"given":"Ond\u0159ej","family":"Fiala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katar\u00edna","family":"Rejlekov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Buchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"\u0160tudentov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandr","family":"Poprach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Vo\u010dka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Ho\u0161ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jind\u0159ich","family":"Kopeck\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Mat\u011bj\u016f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ane\u017eka","family":"Zem\u00e1nkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Spisarov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Tkadlecov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Priester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Kou\u0159il","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radka","family":"Lohynsk\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Grmelov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Savka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katar\u00edna","family":"\u0160tef\u00e1nikov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Obertov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"\u0160ikov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Str\u00e1nsk\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohuslav","family":"Melichar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrik","family":"Palacka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,21]]},"reference":[{"key":"32593_CR1","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl. J. Med. 373, 1803\u20131813. https:\/\/doi.org\/10.1056\/NEJMoa1510665 (2015).","journal-title":"N Engl. J. Med."},{"key":"32593_CR2","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","volume":"35","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. Renal cell carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 35, 692\u2013706. https:\/\/doi.org\/10.1016\/j.annonc.2024.05.537 (2024).","journal-title":"Ann. Oncol."},{"key":"32593_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.02.020","author":"A Bex","year":"2025","unstructured":"Bex, A. et al. European association of urology guidelines on renal cell carcinoma: the 2025 update. Eur. Urol. https:\/\/doi.org\/10.1016\/j.eururo.2025.02.020 (2025).","journal-title":"Eur. Urol."},{"key":"32593_CR4","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer, R. J. et al. Nivolumab plus ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N Engl. J. Med. 378, 1277\u20131290. https:\/\/doi.org\/10.1056\/NEJMoa1712126 (2018).","journal-title":"N Engl. J. Med."},{"key":"32593_CR5","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri, T. K. et al. Nivolumab plus Cabozantinib versus Sunitinib for advanced renal-cell carcinoma. N Engl. J. Med. 384, 829\u2013841. https:\/\/doi.org\/10.1056\/NEJMoa2026982 (2021).","journal-title":"N Engl. J. Med."},{"key":"32593_CR6","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer, R. et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl. J. Med. 384, 1289\u20131300. https:\/\/doi.org\/10.1056\/NEJMoa2035716 (2021).","journal-title":"N Engl. J. Med."},{"key":"32593_CR7","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer, R. J. et al. Avelumab plus axitinib versus Sunitinib for advanced renal-cell carcinoma. N Engl. J. Med. 380, 1103\u20131115. https:\/\/doi.org\/10.1056\/NEJMoa1816047 (2019).","journal-title":"N Engl. J. Med."},{"key":"32593_CR8","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini, B. I. et al. Pembrolizumab plus axitinib versus Sunitinib for advanced renal-cell carcinoma. N Engl. J. Med. 380, 1116\u20131127. https:\/\/doi.org\/10.1056\/NEJMoa1816714 (2019).","journal-title":"N Engl. J. Med."},{"key":"32593_CR9","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41568-020-0283-9","volume":"20","author":"S Grisaru-Tal","year":"2020","unstructured":"Grisaru-Tal, S., Itan, M., Klion, A. D. & Munitz, A. A new dawn for eosinophils in the tumour microenvironment. Nat. Rev. Cancer. 20, 594\u2013607. https:\/\/doi.org\/10.1038\/s41568-020-0283-9 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"32593_CR10","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/ni.3159","volume":"16","author":"R Carretero","year":"2015","unstructured":"Carretero, R. et al. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8\u207a T cells. Nat. Immunol. 16, 609\u2013617. https:\/\/doi.org\/10.1038\/ni.3159 (2015).","journal-title":"Nat. Immunol."},{"key":"32593_CR11","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2326-6066.CIR-18-0543","volume":"7","author":"H Reichman","year":"2019","unstructured":"Reichman, H. et al. Activated eosinophils exert anti-tumorigenic activities in colorectal cancer. Cancer Immunol. Res. 7, 388\u2013400. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0543 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"32593_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0065-2776(08)01003-1","volume":"101","author":"C Blanchard","year":"2009","unstructured":"Blanchard, C. & Rothenberg, M. E. Biology of the eosinophil. Adv. Immunol. 101, 81\u2013121. https:\/\/doi.org\/10.1016\/S0065-2776(08)01003-1 (2009).","journal-title":"Adv. Immunol."},{"key":"32593_CR13","unstructured":"Simson, L. & Foster, P. S. Eosinophils and cancer. In: (eds Rothenberg, M. E. & Hogan, S. P.) Eosinophils in Health and Disease. Elsevier; :509\u2013523. (2013)."},{"key":"32593_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumours. J. Natl. Cancer Inst. 92, 205\u2013216. https:\/\/doi.org\/10.1093\/jnci\/92.3.205 (2000).","journal-title":"J. Natl. Cancer Inst."},{"key":"32593_CR15","first-page":"805","volume":"1","author":"JA Sosman","year":"1995","unstructured":"Sosman, J. A. et al. Evidence for eosinophil activation in cancer patients receiving Recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration. Clin. Cancer Res. 1, 805\u2013812 (1995).","journal-title":"Clin. Cancer Res."},{"key":"32593_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s002620050349","volume":"44","author":"KA Ellem","year":"1997","unstructured":"Ellem, K. A. et al. A case report: immune responses and clinical course of the first human use of granulocyte\/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunol. Immunother. 44, 10\u201320 (1997).","journal-title":"Cancer Immunol. Immunother"},{"key":"32593_CR17","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1002\/eji.200323634","volume":"33","author":"HU Simon","year":"2003","unstructured":"Simon, H. U. et al. Interleukin-2 primes eosinophil degranulation in hypereosinophilia and wells\u2019 syndrome. Eur. J. Immunol. 33, 834\u2013839. https:\/\/doi.org\/10.1002\/eji.200323634 (2003).","journal-title":"Eur. J. Immunol."},{"key":"32593_CR18","doi-asserted-by":"publisher","first-page":"5453","DOI":"10.1158\/1078-0432.CCR-15-0676","volume":"21","author":"C Gebhardt","year":"2015","unstructured":"Gebhardt, C. et al. Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab. Clin. Cancer Res. 21, 5453\u20135459. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0676 (2015).","journal-title":"Clin. Cancer Res."},{"key":"32593_CR19","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1158\/1078-0432.CCR-15-2206","volume":"22","author":"A Martens","year":"2016","unstructured":"Martens, A. et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin. Cancer Res. 22, 2908\u20132918. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2206 (2016).","journal-title":"Clin. Cancer Res."},{"key":"32593_CR20","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-16-0583","volume":"22","author":"B Weide","year":"2016","unstructured":"Weide, B. et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin. Cancer Res. 22, 5487\u20135496. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0583 (2016).","journal-title":"Clin. Cancer Res."},{"key":"32593_CR21","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1111\/bjh.14705","volume":"181","author":"I Hude","year":"2018","unstructured":"Hude, I. et al. Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical hodgkin lymphoma patients treated with PD1 Inhibition. Br. J. Haematol. 181, 837\u2013840. https:\/\/doi.org\/10.1111\/bjh.14705 (2018).","journal-title":"Br. J. Haematol."},{"key":"32593_CR22","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.lungcan.2020.08.015","volume":"150","author":"X Chu","year":"2020","unstructured":"Chu, X. et al. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors. Lung Cancer. 150, 76\u201382. https:\/\/doi.org\/10.1016\/j.lungcan.2020.08.015 (2020).","journal-title":"Lung Cancer"},{"key":"32593_CR23","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/CJI.0000000000000372","volume":"44","author":"JM Mota","year":"2021","unstructured":"Mota, J. M. et al. Pretreatment eosinophil counts in patients with advanced or metastatic urothelial carcinoma treated with anti-PD-1\/PD-L1 checkpoint inhibitors. J. Immunother. 44, 248\u2013253. https:\/\/doi.org\/10.1097\/CJI.0000000000000372 (2021).","journal-title":"J. Immunother"},{"key":"32593_CR24","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3390\/immuno1030017","volume":"1","author":"E Giommoni","year":"2021","unstructured":"Giommoni, E. et al. Eosinophil count as predictive biomarker of immune-related adverse events in immune checkpoint inhibitors therapies in oncological patients. Immuno 1, 253\u2013263. https:\/\/doi.org\/10.3390\/immuno1030017 (2021).","journal-title":"Immuno"},{"key":"32593_CR25","doi-asserted-by":"publisher","first-page":"6705","DOI":"10.1002\/cam4.4208","volume":"10","author":"T Herrmann","year":"2021","unstructured":"Herrmann, T. et al. Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study. Cancer Med. 10, 6705\u20136713. https:\/\/doi.org\/10.1002\/cam4.4208 (2021).","journal-title":"Cancer Med."},{"key":"32593_CR26","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1002\/ijc.32829","volume":"146","author":"X Zheng","year":"2020","unstructured":"Zheng, X. et al. CTLA4 Blockade promotes vessel normalization in breast tumors via the accumulation of eosinophils. Int. J. Cancer. 146, 1730\u20131740. https:\/\/doi.org\/10.1002\/ijc.32829 (2020).","journal-title":"Int. J. Cancer"},{"key":"32593_CR27","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","volume":"26","author":"IG House","year":"2020","unstructured":"House, I. G. et al. Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint Blockade. Clin. Cancer Res. 26, 487\u2013504. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1868 (2020).","journal-title":"Clin. Cancer Res."},{"key":"32593_CR28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3389\/fcell.2019.00329","volume":"7","author":"J Yoon","year":"2019","unstructured":"Yoon, J. et al. Eosinophil activation by toll-like receptor 4 ligands regulates macrophage polarization. Front. Cell. Dev. Biol. 7, 329. https:\/\/doi.org\/10.3389\/fcell.2019.00329 (2019).","journal-title":"Front. Cell. Dev. Biol."},{"key":"32593_CR29","doi-asserted-by":"publisher","first-page":"eabc7609","DOI":"10.1126\/sciadv.abc7609","volume":"7","author":"JN Cheng","year":"2021","unstructured":"Cheng, J. N. et al. Radiation-induced eosinophils improve cytotoxic T lymphocyte recruitment and response to immunotherapy. Sci. Adv. 7, eabc7609. https:\/\/doi.org\/10.1126\/sciadv.abc7609 (2021).","journal-title":"Sci. Adv."},{"key":"32593_CR30","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s12032-018-1084-9","volume":"35","author":"BM Lang","year":"2018","unstructured":"Lang, B. M. et al. Long-term survival with modern therapeutic agents against metastatic melanoma: Vemurafenib and ipilimumab in a daily life setting. Med. Oncol. 35, 24. https:\/\/doi.org\/10.1007\/s12032-018-1084-9 (2018).","journal-title":"Med. Oncol."},{"key":"32593_CR31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2217\/imt-2016-0138","volume":"9","author":"A Moreira","year":"2017","unstructured":"Moreira, A., Leisgang, W., Schuler, G. & Heinzerling, L. Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy. Immunotherapy 9, 115\u2013121. https:\/\/doi.org\/10.2217\/imt-2016-0138 (2017).","journal-title":"Immunotherapy"},{"key":"32593_CR32","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10238-024-01370-8","volume":"24","author":"A Yoshimura","year":"2024","unstructured":"Yoshimura, A. et al. The prognostic impact of peripheral blood eosinophil counts in metastatic renal cell carcinoma patients treated with nivolumab. Clin. Exp. Med. 24, 111. https:\/\/doi.org\/10.1007\/s10238-024-01370-8 (2024).","journal-title":"Clin. Exp. Med."},{"key":"32593_CR33","doi-asserted-by":"publisher","first-page":"274e1","DOI":"10.1016\/j.clgc.2020.10.003","volume":"19","author":"SL Verhaart","year":"2021","unstructured":"Verhaart, S. L. et al. Real-world data of nivolumab for patients with advanced renal cell carcinoma in the netherlands: an analysis of toxicity, efficacy, and predictive markers. Clin. Genitourin. Cancer. 19, 274e1\u201327416. https:\/\/doi.org\/10.1016\/j.clgc.2020.10.003 (2021).","journal-title":"Clin. Genitourin. Cancer"},{"key":"32593_CR34","doi-asserted-by":"publisher","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"Templeton, A. J. et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J. Natl. Cancer Inst. 106, dju124. https:\/\/doi.org\/10.1093\/jnci\/dju124 (2014).","journal-title":"J. Natl. Cancer Inst."},{"key":"32593_CR35","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.critrevonc.2013.03.010","volume":"88","author":"GJ Guthrie","year":"2013","unstructured":"Guthrie, G. J. et al. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit. Rev. Oncol. Hematol. 88, 218\u2013230. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.03.010 (2013).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"32593_CR36","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1158\/1055-9965.EPI-14-0016","volume":"23","author":"AJ Templeton","year":"2014","unstructured":"Templeton, A. J. et al. Prognostic role of platelet-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol. Biomarkers Prev. 23, 1204\u20131212. https:\/\/doi.org\/10.1158\/1055-9965.EPI-14-0016 (2014).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"32593_CR37","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40364-021-00334-4","volume":"9","author":"MD Tucker","year":"2021","unstructured":"Tucker, M. D. et al. Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma. Biomark. Res. 9, 80. https:\/\/doi.org\/10.1186\/s40364-021-00334-4 (2021).","journal-title":"Biomark. Res."},{"key":"32593_CR38","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.3390\/cancers14153830","volume":"14","author":"YW Chen","year":"2022","unstructured":"Chen, Y. W. et al. The association between a decrease in on-treatment neutrophil-to-eosinophil ratio at week 6 after ipilimumab plus nivolumab initiation and improved clinical outcomes in metastatic renal cell carcinoma. Cancers (Basel). 14, 3830. https:\/\/doi.org\/10.3390\/cancers14153830 (2022).","journal-title":"Cancers (Basel)"},{"key":"32593_CR39","doi-asserted-by":"publisher","first-page":"e000181","DOI":"10.1136\/bmjonc-2023-000181","volume":"3","author":"M Tucker","year":"2024","unstructured":"Tucker, M. et al. Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or Sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN renal 101 trial. BMJ Oncol. 3, e000181. https:\/\/doi.org\/10.1136\/bmjonc-2023-000181 (2024).","journal-title":"BMJ Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32593-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32593-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32593-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:06:24Z","timestamp":1769213184000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32593-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,21]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["32593"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-32593-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,21]]},"assertion":[{"value":"26 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ond\u0159ej Fiala received honoraria from Novartis, Janssen, Merck, Ipsen, BMS, MSD, Pierre Fabre, and Pfizer for consultations and lectures unrelated to this project.Katarina Rejlekova has received payment for speakers\u2019 bureaus, presentations, lectures or educational events from Bayer, Novartis, Ipsen, Merck and Pfizer. All the above are unrelated to this paper.Tomas Buchler has received research support: AstraZeneca, Roche, Bristol Myers Squibb, Exelixis, Merck KGaA, MSD, and Novartis; consulting fees from Bristol Myers Squibb, Astellas, Janssen, and Sanofi\/Aventis; payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Ipsen, Bristol Myers Squibb, AstraZeneca, Roche, Servier, Accord, MSD, and Pfizer. All unrelated to the present paper. All of the above are unrelated to the present paper.Hana \u0160tudentov\u00e1 has received consulting fees from Bristol Myers Squibb, MSD, Ipsen, Novartis, Astellas and Janssen; payment or honoraria for lectures, presentations, speakers\u2019 bureaus, or educational events from Ipsen, Merck, Bristol Myers Squibb, Novartis, MSD, and Pfizer. All of the above are unrelated to the present paper.Alexandr Poprach has received consulting fees from Bristol Myers Squibb, Roche, Eisai, Astellas, Johnson & Johnson, Zentiva, Novartis, Pfizer, Merck, MSD, Ipsen; payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Ipsen, Bristol Myers Squibb, MSD, Merck, Novartis, Eisai, Astellas, Johnson & Johnson and Pfizer. All of the above are unrelated to the present paper.Michal Vo\u010dka has received consulting fees from Merck, Roche, MSD; payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from BMS, MSD, Merck, Novartis, AstraZeneca, Roche and Pfizer. All of the above are unrelated to the present paper.Jind\u0159ich Kopeck\u00fd has received consulting fees from Bristol Myers Squibb, Novartis, Pfizer, Merck, MSD, Ipsen; payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Ipsen, Bristol Myers Squibb, MSD, Merck, Novartis and Pfizer. All of the above are unrelated to the present paper.Martin Mat\u011bj\u016f has received consulting fees from Novartis, MSD, Astellas; payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Ipsen, BMS, MSD, Merck, Novartis, Eisa, AstraZeneca, Roche and Pfizer. All of the above are unrelated to the present paper.Radka Lohynsk\u00e1 has received payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Roche, Janssen, Bristol Myers Squibb, MSD and Merck. All of the above are unrelated to the present paper.Bohuslav Melichar received honoraria from Novartis, Pfizer, Bayer-Schering, Astellas, and Roche for lectures and advisory boards unrelated to this project.Patrik Palacka has received consulting fees from Bristol Myers Squibb, Astellas, Pfizer and Merck; payment for speakers\u2019 bureaus, presentations, lectures or educational events from Bayer, MSD, Novartis, Ipsen, Janssen, Bristol Myers Squibb, Merck, Astellas and Pfizer. All the above are unrelated to this paper.All other authors have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors have approved the manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study was performed in accordance with the study protocol, the ethical principles stated in the Declaration of Helsinki as well as those indicated in the International Conference on Harmonization (ICH) Note for Guidance on Good Clinical Practice (GCP; ICH E6, 1995), and all applicable regulatory requirements. RENIS II registry was approved by the Ethics Committee of the Masaryk Memorial Cancer Institute, Brno, Czech Republic. All patients provided informed consent. For deceased or untraceable individuals, the Institutional Review Board of the coordinating center waived the requirement for consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"2811"}}